Tag: Myasthenia Gravis
FDA Approves Zilbrysq for Generalized Myasthenia Gravis
Approval granted for once-daily, self-administered treatment in patients with anti-acetylcholine receptor-antibody-positive disease
FDA Approves Subcutaneous Vyvgart Hytrulo for Generalized Myasthenia Gravis
Trial shows similar reductions in anti-acetylcholine receptor antibody levels to the intravenous formulation
FDA Approves First-in-Class Treatment for Myasthenia Gravis
Vyvgart is the first neonatal Fc receptor blocker to be approved to treat generalized myasthenia gravis in patients testing positive for AChR antibody
Thymectomy + PDN Beneficial for Non-Thymomatous Myasthenia Gravis
Thymectomy plus prednisone confers benefit versus prednisone alone at 5 years in myasthenia gravis
Thymectomy Improves Outcomes in Myasthenia Gravis
Study compared thymectomy plus alternate-day prednisone with alternate-day prednisone alone
Autologous HSCT Can Result in Remission in Myasthenia Gravis
Treatment linked to durable, symptom-free, treatment-free remission in seven cases of MG
